Tisotumab vedotin is an antibody drug conjugate (ADC) targeting tissue factor (TF), formed by covalently linking a fully human monoclonal antibody (TF-011) against TF with the microtubule disruptor Monomethyll Auristatin E (MMAE) (HY-15162), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Tisotumab vedotin has immunomodulatory and anti-tumor activities, and can be used in the study of advanced or metastatic solid tumors such as cervical cancer[1][2][3].
Molekulargewicht:
152000 (average)
Reinheit:
99.69
CAS Nummer:
[1418731-10-8]
Target-Kategorie:
Antibody-Drug Conjugates (ADCs)
Anwendungsbeschreibung:
MCE Product type: ADC Related
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten